Insulin Detemir — supply status, manufacturers & alternatives

Insulin Detemir

—

🇦🇺 AUST R 172213 · Novo Nordisk Pharmaceuticals Pty Ltd

In supply · Australia

Levemir

In supply · 🇦🇺 Australia · short in🇺🇸 US

In supply in Australia

Reading today’s signals…

🇦🇺 AUAEMPA$61.61DPMQ A$346.74details →

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Insulin Detemir

Brand names	Levemir

Therapeutic category	Auto-created by FDA Drug Enforcement — Full Recall Database scraper

Controlled substance	No

Marketing-authorisation holders	Novo Nordisk Pharmaceuticals Pty Ltd

Registrations on file	2

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 PBS · July 2026

🇦🇺 AU

● Official price on file

Ex-manufacturer

A$61.61

AEMP

Dispensed (DPMQ)

A$346.74

incl. fees

Pack

insulin detemir 100 units/mL injection, 5 x 3 mL pen devices

Source: PBSEffective July 2026 · AUD

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders2 registrations · 1 MA holder

Product	Strength	Form	Market	MA holder	Status
LEVEMIR PENFILL insulin detemir	—	—	🇦🇺 AU	Novo Nordisk Pharmaceuticals Pty Ltd	Active
LEVEMIR FLEXPEN insulin detemir	—	—	🇦🇺 AU	Novo Nordisk Pharmaceuticals Pty Ltd	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.